"Furthermore, although the reviewed studies have consistently...

"Furthermore, although the reviewed studies have consistently shown the cardioprotective effects of SGLT2 inhibitors against cancer treatment–related cardiotoxicity in tumor-free models, none has yet concurrently demonstrated the cardioprotective and the anticancer effects of SGLT2 inhibitors in tumor-bearing model"

Definitely a space to watch, the SGLT2s are ubiquitous in cardiorenal disease and form part of the fundamental 4 pillars of heart failure treatments along with the ARNIs, beta-blockers and MRAs. They will get great physician buy-in if they can demonstrate cardioprotection in an RCT.

Of course the holy-grail is cardioprotection AND anti-cancer synergy which is yet to be proven in SGLT2s but this could pose a threat to bisantrene if proven.

Gret find @HeyLine